donanemab

The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.

The clinic will provide two medications that can slow the progression of the disease in early stages: Leqembi and Kisunla. The Roskamp Institute plans to open the facility in September.

The FDA will make the final decision on approval later this year. If the agency agrees with advisers, donanemab would only be the second drug approved to slow cognitive decline due to Alzheimer’s.

Treatments that can slow the disease in some patients have recently become more widely available, but not everyone can benefit.

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.